Evidence map›Paper›PMID 32921587›Full record

Trial reportBiological psychiatry. Cognitive neuroscience and neuroimaging2021

Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder.

Cherise R Chin Fatt, Crystal Cooper, Manish K Jha, Sina Aslan, Bruce Grannemann, Benji Kurian, Tracy L Greer, Maurizio Fava, Myrna Weissman, Patrick J McGrath and 4 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Cherise R Chin FattDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.
Crystal CooperDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.
Manish K JhaDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.
Sina AslanDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas; Advance MRI, LLC, Frisco, Texas.
Bruce GrannemannDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.
Benji KurianDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.
Tracy L GreerDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.
Maurizio FavaDepartment of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
Myrna WeissmanNew York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, New York.
Patrick J McGrathNew York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York, New York.
Ramin V ParseyDepartment of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Amit EtkinDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Stanford Neurosciences Institute, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education and Clinical Center, VA Palo Alto Healthcare System, Palo Alto, California.
Mary L PhillipsDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Madhukar H TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: madhukar.trivedi@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USColumbia University · USIcahn School of Medicine at Mount Sinai · USMassachusetts General Hospital · USStony Brook School · USUniversity of Pittsburgh · USVA Palo Alto Health Care System · US

Funding

Establishing Moderators/Biosignatures of Antidepressant Response- Clinical CareU01MH092221 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2010 to 2015
$9.7M
Biosignatures of Treatment Remission in Major DepressionU01MH092250 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MCGRATH, PATRICK J, PARSEY, RAMIN V. · 2010 to 2015
$8.9M
NIMH NIH HHS U01 MH092221NIMH NIH HHS U01 MH092250
6 · The paper itself

Abstract

backgroundMajor depressive disorder is associated with abnormal connectivity across emotion and reward circuits as well as other established circuits that may negatively impact treatment response. The goal of this study was to perform an exploratory reanalysis of archival data from a clinical trial to identify moderators of treatment outcome of sertraline over placebo.

methodsEMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care) study participants completed magnetic resonance imaging before randomization to either sertraline or placebo for 8 weeks (n = 279). Seed-based functional connectivity was computed using 4 bilateral seeds (2 spheres defined bilaterally): amygdala, dorsolateral prefrontal cortex (DLPFC), subcallosal cingulate cortex, and ventral striatum. Functional connectivity maps were generated, principal component analysis was performed, linear mixed effects models were used to determine moderators of treatment outcome, and post hoc analyses were used to determine level of connectivity (low and high, -1 and +1 SD from the mean) that was most sensitive to improved depression severity (baseline to week 8) based on treatment.

resultsGreater mean reduction in the 17-item Hamilton Rating Scale for Depression score by 8 weeks occurred with sertraline relative to placebo when connectivity in the DLPFC was low (3-way interaction test, p = .05). Conditional on low connectivity in the DLPFC and subcallosal cingulate cortex and high connectivity in the ventral striatum and amygdala, there was on average a 4.8-point greater reduction in the 17-item Hamilton Rating Scale for Depression score with sertraline relative to placebo (p = .003).

conclusionsThe level of functional connectivity seeded in both the DLPFC and the subcallosal cingulate cortex networks may play an important role in identifying a favorable response to sertraline over placebo.

Indexed as

Major Depressive DisorderSertralineAntidepressive AgentsGyrus CinguliHumansPrefrontal CortexAntidepressive AgentsSertralineAmygdalaAntidepressant responseCentral executive networkDepressionDorsolateral prefrontal cortexEMBARCfcMRIFunctional connectivityNCT01407094Resting stateSubcallosal cingulateVentral striatum

Identifiers

PMID32921587
PMCPMC10177661
OpenAlexW3041665639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.